Trial record 1 of 1 for:
regeneron capella
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02418754 |
|
Recruitment Status :
Terminated
(No additional efficacy seen with REGN2176-3 over aflibercept alone)
First Posted : April 16, 2015
Results First Posted : October 26, 2020
Last Update Posted : October 26, 2020
|
Sponsor:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Regeneron Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.
The secondary objectives of the study were the following:
- To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12)
- To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI.
- To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Neovascular Age-Related Macular Degeneration | Drug: REGN2176-3 Drug: Intravitreal Aflibercept Injection (IAI) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 505 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration |
| Actual Study Start Date : | May 5, 2015 |
| Actual Primary Completion Date : | August 17, 2016 |
| Actual Study Completion Date : | April 3, 2017 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Age-related macular degeneration
MedlinePlus related topics:
Macular Degeneration
| Arm | Intervention/treatment |
|---|---|
|
Experimental: REGN2176-3 (1 mg: 2 mg)
Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
|
Drug: REGN2176-3 |
|
Experimental: REGN2176-3 (3 mg: 2 mg)
Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
|
Drug: REGN2176-3 |
|
Experimental: Intravitreal Aflibercept Injection (IAI) 2 mg
IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
|
Drug: Intravitreal Aflibercept Injection (IAI)
Other Name: Eylea® |
|
Experimental: REGN2176-3 (3 mg: 2 mg) to IAI 2 mg
Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
|
Drug: Intravitreal Aflibercept Injection (IAI)
Other Name: Eylea® |
|
Experimental: IAI 2 mg to REGN2176-3 (3 mg:2 mg)
IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
|
Drug: REGN2176-3 |
Primary Outcome Measures :
- Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12 [ Time Frame: Baseline, Week 12 ]Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
Secondary Outcome Measures :
- Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT) [ Time Frame: Baseline, Week 12 ]CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
- Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT) [ Time Frame: Week 12 ]CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.
- Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA) [ Time Frame: Baseline, Week 12 ]The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm^2 on the retina; lower values represent better outcomes.
- Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA) [ Time Frame: Baseline, Week 12 ]Total Lesion Size was assessed by Fluorescein Angiography.
- Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS) [ Time Frame: Week 12 ]Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.
- Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT) [ Time Frame: Baseline, Week 12 ]SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.
- Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT) [ Time Frame: Baseline, Week 12 ]CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Men or women ≥50 years of age
- Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea
- BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit
- Provide signed informed consent
Key Exclusion Criteria:
- Any prior treatment with anti-VEGF treatment in the study eye
- Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors
- Dense fibrotic scar or atrophy in the study eye involving the center of the fovea
- Presence of retinal pigment epithelial tears or rips involving the macula in the study eye
- Prior vitrectomy in the study eye
- Any history of macular hole of stage 2 and above in the study eye
- Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery
- History of corneal transplant in the study eye
- Evidence of diabetic retinopathy or diabetic macular edema in either eye
- Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02418754
Locations
Show 84 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
| Study Director: | Clinical Trial Management | Regeneron Pharmaceuticals |
| Responsible Party: | Regeneron Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT02418754 |
| Obsolete Identifiers: | NCT02603484 |
| Other Study ID Numbers: |
R2176-3-AMD-1417 |
| First Posted: | April 16, 2015 Key Record Dates |
| Results First Posted: | October 26, 2020 |
| Last Update Posted: | October 26, 2020 |
| Last Verified: | October 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Macular Degeneration Wet Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Aflibercept |
Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |